Roxudo (Roxadustat) – 20 mg Tablets

Description

Roxudo, manufactured by CCL Pharmaceuticals, utilizes the active ingredient Roxadustat to effectively address anemia in patients living with chronic kidney disease, regardless of their dialysis status. Unlike traditional therapies that rely on injecting pre-formed hormones, Roxudo works by activating the body’s natural defense mechanism against low oxygen levels. By inhibiting the prolyl hydroxylase enzyme, it stabilizes the HIF complex, which coordinates an increase in internal erythropoietin production and significantly improves iron absorption and utilization to help restore healthy hemoglobin levels.

Precise Dosing and Convenience The 20 mg strength offers healthcare providers critical dosing flexibility when tailoring, initiating, or adjusting treatment regimens to a patient’s exact metabolic response. Packaged in a compact layout of 12 tablets, it simplifies daily oral routine compliance compared to frequent clinical visits required for injectable options. Produced under strict quality standards by CCL, Roxudo 20 mg represents a patient-friendly, modern pharmaceutical approach to improving energy and systemic health in chronic kidney care.